Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Provexis ( (GB:PXS) ) has issued an update.
Provexis plc announced the grant of 56,000,000 options and 58,730,000 warrants over ordinary shares to its CEO, Ian Ford, and to certain scientific, sales, and marketing consultants. This move follows discussions with the company’s larger shareholders and is aimed at aligning management and consultant incentives with company performance, potentially impacting up to 10% of the company’s issued share capital. The grant of options to Ian Ford is a related party transaction, with the directors, excluding Ford, deeming the terms fair and reasonable for shareholders.
More about Provexis
Provexis plc is a company focused on the development, licensing, and sale of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient. Fruitflow is a natural ingredient that helps with platelet aggregation, promoting cardiovascular health by facilitating smooth blood flow. The company markets a dietary supplement containing Fruitflow and Omega-3, available via mail order and on Amazon. Provexis collaborates with BYHEALTH, a major Chinese dietary supplement company, for launching Fruitflow-based products in China, supported by extensive clinical studies.
YTD Price Performance: -0.44%
Average Trading Volume: 568,945
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £15.78M
Find detailed analytics on PXS stock on TipRanks’ Stock Analysis page.
